Inipharm to present Pharmacokinetic data from phase 1 trial of INI-822 at EASL
25 May 2024 //
PHARMABIZ
Inipharm To Present INI-822 PK Phase 1 Data
22 May 2024 //
BUSINESSWIRE
Inipharm Initiates Dosing in Ph 1 Study of Small Molecule Inhibitor of HSD17B13
30 Nov 2023 //
BUSINESSWIRE
Inipharm’s Development Candidate INI-822 Shows Improvements in Markers of Liver Homeostasis
07 Jun 2023 //
BUSINESSWIRE
Inipharm to Present Data on Anti-Fibrotic Targeting HSD17B13
25 Oct 2022 //
BUSINESSWIRE
Inipharm Appoints Chuhan Chung, M.D, as CMO to Advance HSD17B13 Program
08 Jun 2022 //
BUSINESSWIRE